The patient with IBD in clinical remission did have one of the highest S100A8 and S100A9 baseline levels, which may fit with elevated calprotectin levels found in SpA patients at risk of bowel inflammation and in IBD patients36. The gene discussed is S100A9; the disease is inflammatory bowel disease.